Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Psychology Research and Behavior Management|December 5, 2023
Neurogenetics and Epigenetics of LonelinessAbdalla Bowirrat, Igor Elman, Catherine A Dennen, et al.Open Journal of Immunology|November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial TherapiesKenneth Blum, Igor Elman, David Han, et al.Frontiers in Public Health|December 3, 2025
Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergiaKai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.Current Pharmaceutical Biotechnology|April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis EraAlireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.Acta Scientific Neurology|September 2, 2025
Dopaminergic Homeostatic Therapy (DHT<sup>™</sup>) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS<sup>®</sup>) ScreeningKai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.Gene & Protein in Disease|May 20, 2024
Identification of stress-induced epigenetic methylation onto dopamine D2 gene and neurological and behavioral consequencesKenneth Blum, Abdalla Bowirrat, David Baron, et al.Current Pharmaceutical Biotechnology|March 14, 2026
Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and AnxietyKenneth Blum, Alexander P L Lewandrowski, Alireza Sharafshah, et al.Neurology (E-Cronicon)|December 29, 2025
Neurospirituality Connectome - Role in Neurology and Reward Deficiency Syndrome (RDS)Kenneth Blum, Eric R Braverman, Milan Makale, et al.Journal of Addiction Psychiatry|September 11, 2025
Precision Genomics: A Reality Having Universal Impact in a New Era of Psychiatry - Lessons Learned, Past and PresentKenneth Blum, Alireza Sharafshah, Jag Khalsa, et al.Research Square|December 3, 2025
Computational GWAS Meta Meta Analysis Revealing Cross Talk Between Cannabis CNR1 and DRD2 Receptors Optimizing Long-Term Outcomes for Cannabis Use Disorder (CUD) By Enhancing Dopamine Homeostasis Promoting High-Quality Cannabis MedicinalsKenneth Blum, Alireza Sharafshah, Jag Khalsa, et al.Pageof 4